Tekla Life Sciences Investors
NYSE:HQLAsset Management
+$0.11 today
- Market cap
- $585.96M
- Beta
- 0.73
- P/E (TTM)
- 2.8
- EPS (TTM)
- $6.52
- Dividend yield
- 11.35%
Volume 0.12M
Average 0.11M
HQL Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Tekla Life Sciences InvestorsNYSE: HQL
Net Margin · Q2 FY2026 · quarter ended Mar 2026
Net margin widens to 135.9%
Net margin was 135.9% in Q2 FY2026, up 395.5 pp from a year earlier. Over 3 fiscal years it widened by 427.4 pp.
Context
- Net margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 99.1%
- Year-over-year change
- +0.7pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 99.1% | +0.7pp |
| FY2024 | 2024-09-30 | 98.4% | +41.6pp |
| FY2023 | 2023-09-30 | 56.8% | +385.0pp |
| FY2022 | 2022-09-30 | -328.3% | -471.6pp |
| FY2021 | 2021-09-30 | 143.3% | — |
Net Margin vs competitors
How HQL compares with its peers on the latest reported figures
- HQL's FY2025 net margin of 99.1% is the 3rd highest of the 10 companies compared; the peer median is 16.8%.
- Its year-over-year change of +0.7 pp is the 4th highest of 10, against a peer median of -17.3 pp.
- Over three fiscal years its change of +427.4 pp compares with a peer median of +35.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 173.6% | +100.9 pp | +185.2 pp | |
| FY2025 | 126.0% | +28.6 pp | +285.5 pp | |
| FY2025 | 99.1% | +0.7 pp | +427.4 pp | |
| LTM Jun 2025 | 77.9% | -8.7 pp | +35.9 pp | |
| LTM Mar 2026 | 62.3% | -17.3 pp | -20.2 pp | |
| LTM Mar 2026 | 16.8% | -29.6 pp | +143.3 pp | |
| LTM Mar 2026 | 12.1% | -29.7 pp | -7.7 pp | |
| LTM Mar 2026 | -0.6% | +15.8 pp | -55.5 pp | |
| LTM Dec 2025 | -74.1% | -231.1 pp | -245.3 pp | |
| LTM Mar 2026 | -515.9% | -394.7 pp | +121.6 pp | |
| Peer median (excluding HQL) | 16.8% | -17.3 pp | +35.9 pp | |
Competitors are the stored peer set for HQL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 45.02M | 31.86M | 39.39M | 86.69M | 86.39M |
| Cost of Revenue | 6.08M | 5.55M | 5.24M | 5.36M | 4.97M |
| Gross Profit | 38.95M | 26.31M | 18.28M | 86.69M | 86.39M |
| Gross Margin | 86.5% | 82.6% | 46.4% | 100.0% | 100.0% |
| Research & Development | 0 | (3) | 0 | 0 | 0 |
| Selling, General & Admin | 844.02K | 1.08M | 903.14K | 1.33M | 743.17K |
| Operating Expenses | 1.16M | 1.35M | 1.17M | 1.39M | 791.57K |
| Depreciation & Amortization | 4.14M | 2.99M | 27.6M | 1.92M | 0 |
| EBITDA | 68.68M | (101.62M) | 49.95M | 87.22M | 85.59M |
| EBITDA Margin | 152.5% | -318.9% | 126.8% | 100.6% | 99.1% |
| Operating Income | 64.53M | (104.6M) | (5.24M) | 85.3M | 85.59M |
| Operating Margin | 143.3% | -328.3% | -13.3% | 98.4% | 99.1% |
| Interest Income | 0 | 50.09K | 204.45K | 1.04M | 349.84K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (7.83K) | 2.42K | 27.6M | 87.22M | 0 |
| Income Before Tax | 64.53M | (104.6M) | 22.35M | 85.3M | 85.59M |
| Pre-Tax Margin | 143.3% | -328.3% | 56.8% | 98.4% | 99.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | 64.53M | (104.6M) | 22.35M | 85.3M | 85.59M |
| Net Margin | 143.3% | -328.3% | 56.8% | 98.4% | 99.1% |
| EPS (Basic) | 2.66 | (4.07) | 0.79 | 3.04 | 2.96 |
| EPS (Diluted) | 2.66 | (4.07) | 0.79 | 3.04 | 2.96 |
| Weighted Avg Shares | 24.26M | 25.68M | 28.29M | 28.06M | 28.87M |
| Weighted Avg Shares (Diluted) | 24.26M | 25.68M | 28.29M | 28.06M | 28.87M |
Tekla Life Sciences Investors
NYSE:HQL
Intrinsic Alpha fair value
Locked
Current Price
$19.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.